Fannin Partners has been awarded a $300,000 Phase I Small Business Innovation Research (SBIR) grant from the National Eye ...

Their conversation focuses on anatomy-driven, individualized approaches and multidisciplinary decision-making for patients ...

Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets –– Pivotal Phase 3 trials in ...

The analyses of progression-free survival (PFS) and overall survival (OS) remain on track for late Q1 2026 in the ongoing Phase 2/3 COMPANION-002 ...

Regeneron shares are up 41% in six months as FDA approvals, strong Dupixent profits and oncology gains lift investor confidence.

Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) has shared an update. Shanghai Henlius Biotech has initiated a first-in-human phase 1 ...

In the expanding field of peptide-based research, a combination of two bioactive molecules—BPC‑157 and TB‑500—has garnered ...

Panelists discuss how higher-dose and dual-pathway anti-VEGF agents enable longer intervals, improved fluid control, and more flexible treatment strategies across retinal vascular diseases. This ...

Panelists discuss how faricimab’s dual VEGF-A and Ang-2 inhibition may offer vascular stability advantages over single-pathway blockade, despite ongoing questions about Ang-2’s independent therapeutic ...

Guest lecturer explores the emerging frontiers in ROP therapy and the evolving ethical, clinical, and technological considerations. Retinopathy of prematurity (ROP) remains among the most challenging ...